Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 12, 2018

AbbVie and Eisai launch auto-injector drug delivery pen

AbbVie has partnered with Eisai and its gastrointestinal diseases unit EA Pharma to introduce an auto-injection delivery pen for Humira drug. 

AbbVie has partnered with Eisai and its gastrointestinal diseases unit EA Pharma to introduce an auto-injection delivery pen for Humira drug.

The auto-injector system is available in two variants of 0.4ml pen to deliver 40mg Humira subcutaneously and 0.8ml for 80mg dose.

Intended to allow simple self-injection, the pen-type devices feature round body to enable easy handling even for patients with a weak grip. They are designed for complete drug injection in around ten seconds.

The systems additionally come with lock function, alert sounds for injection start and finish, along with an inspection window. These devices contain the same drug solution as the standard pre-filled syringes.

Humira is a fully human anti-TNF-α monoclonal antibody that neutralises tumour necrosis factor α (TNF-α) protein associated with the inflammatory response of autoimmune diseases.

“The pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection.”

In Japan, the drug is indicated for rheumatoid arthritis, plaque and arthritic psoriasis, ankylosing spondylitis, intestinal Behçet’s disease, polyarticular juvenile idiopathic arthritis, pustular psoriasis and moderate to severe ulcerative colitis.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

It is also approved to treat non-infectious uveitis, posterior uveitis or panuveitis, and as an induction and maintenance therapy for moderate to severely active Crohn’s disease.

Humira 0.8ml syringe and pen for 80mg subcutaneous injection have yet to be approved for treating polyarticular juvenile idiopathic arthritis.

A statement from Eisai read: “The newly launched pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection.

“AbbVie, Eisai and EA Pharma continue to promote and provide information on the proper use of Humira while making further contributions to improve the quality of life of patients.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU